With King in its fold, Pfizer — which makes Lyrica and Celebrex — believes it can build an industry-leading portfolio of pain relievers. Among King’s most appealing entrants in that market is the new Embeda, designed to preve…
Microsoft has unveiled the initial lineup of smartphones that will use its new mobile OS. Analysts seem impressed, but they warn that the software giant has a huge task ahead to lure consumers away from Apple iPhones and Google…
Alexza Pharmaceuticals shares are tanking in early trading after the company announced today that the U.S. Food and Drug Administration has not approved its AZ-004, an antipsychotic inhaled drug for treating agitation in schizo…
Jazz Pharmaceuticals shares slumped more than 5% in premarket trading Monday after the company announced that the FDA had denied approval for its fibromyalgia treatment, sodium oxybate. While approved to treat narcolepsy, sodi…
What factors can push Apple to keep improving its performance? And what could slow down the stock’s relentless rise? Here are six things — four positive, two negative — that could help determine Apple’s price in coming months…